Martínez, A <br/><br/>
An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia.  [electronic resource] 

 -  Cytometry  Apr 1999 
 - 70-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0196-4763 
<br/><br/><label>Standard No.: </label>10.1002/(sici)1097-0320(19990415)38:2<70::aid-cyto4>3.0.co;2-s  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antigens, CD34--immunology<br/>Antineoplastic Agents--therapeutic use<br/>Bone Marrow Cells--immunology<br/>Child<br/>Female<br/>Hematopoietic Stem Cells--immunology<br/>Humans<br/>Immunophenotyping<br/>Leukemia, Myeloid--drug therapy<br/>Lymphocytes--immunology<br/>Male<br/>Middle Aged<br/>Predictive Value of Tests<br/>Prognosis<br/>Recurrence<br/>Treatment Outcome